The world's first oral selective TYK2 transformer inhibitor was approved

The US Food and Drug Administration (FDA) approved the world's first oral chronicic oscillatanicase 2 (TYK2) destructor Deucravacitinib on September 9th. Patients with psoriasis. Deucravacitinib is the world's first Tyk2 inhibitor, which is currently approved, and is the first innovative oral drug to treat severe plaques psoriasis in the past 10 years.

The approval is based on the results of two key III clinical studies: POETYK PSO-1 and POETYK PSO-2. The results of the study showed that among 1,684 patients with severe plaques in the age of 18 and above, the efficacy of Deucravacitinib for the treatment of Deucravacitinib once a day is better than placebo and twice Apster tablets. The efficacy advantages of Deucravacitinib are reflected in the 16th and 24th weeks, and the response rate for Deucravacitinib can last until the 52nd week.

"Given that Deucravacitinib has the advantage of skin lesions in the POETYK PSO research, this therapy is expected to become a new standard for oral treatment for patients with medium-weight plaques psoriasis." Poeyk PSO-1 clinical trial researcher April Armstrong, deputy dean and professor of dermatology, doctor of medical, and a master's degree in public health, said "patients with medium -weight plaques are facing a huge disease burden, and Deucravacitinib will be a popular front -line system therapy Program."

In terms of security, POETYK PSO research shows that in the 16th week, the most common adverse reactions among the Deucravacitinib therapy group were upper respiratory tract infections (19.2%), etc., and the proportion of drug discontinue due to adverse reactions was low.

Psoriasis is a common chronic, systematic immune media, which seriously damages the health, quality of life and work efficiency of patients, and nearly a quarter of patients are moderate to severe psoriasis. As high as 90%of patients suffer from plaques -like psoriasis, they are characterized by clear circular or oval plaques with clear boundaries. The surface is usually covered with silver -white scales.

Deucravacitinib can inhibit the signal conduction of key cytokine (IL) -23, IL-12, and 1 interferon (IFN) of key cytokine (IL), IL-12, and 1 interferon (IFN). It is combined with the regulatory domain of TYK2 to stabilize the inhibitory interaction between the regulatory domain and the catalytic domain of the kinase.

Earlier in July, the official website of the Drug Review Center (CDE) of the State Drug Administration showed that Deucravacitinib's listing application has been accepted.

Source: Volkswagen.com

- END -